Takagi T, Satake N, Shibata S
Eur J Pharmacol. 1983 Jun 3;90(2-3):297-9. doi: 10.1016/0014-2999(83)90254-6.
In isolated basilar arteries, FR 34235 (FR), a new Ca2+ entry blocker, inhibited the contractile response to potassium, norepinephrine and 5-hydroxytryptamine (5-HT) in a dose-dependent manner. The potency of the inhibitory action of FR was in the following order: potassium greater than 5-HT greater than norepinephrine. Nifedipine had a similar inhibitory action on the responses. Nimodipine had no inhibitory effect on the response to norepinephrine but suppressed the responses to potassium and 5-HT.
在离体基底动脉中,新型钙通道阻滞剂FR 34235(FR)以剂量依赖性方式抑制对钾、去甲肾上腺素和5-羟色胺(5-HT)的收缩反应。FR的抑制作用强度顺序如下:钾>5-HT>去甲肾上腺素。硝苯地平对这些反应有类似的抑制作用。尼莫地平对去甲肾上腺素的反应无抑制作用,但可抑制对钾和5-HT的反应。